Compare Amphastar Pharmaceuticals Inc (AMPH) vs Crowdstrike Holdings Inc (CRWD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Crowdstrike Holdings Inc — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M), while Crowdstrike Holdings Inc trades at $221.2 (market cap $229.27B). The key difference: Crowdstrike Holdings Inc is far larger — about 265.4× Amphastar Pharmaceuticals Inc's market cap, and Crowdstrike Holdings Inc is trading nearer its 52-week high, Amphastar Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| AMPH | CRWD | |
|---|---|---|
Market Cap | $863.95M | $229.27B |
Sector | Health | Technology |
52-Week High | $30.81 | $225.16 |
52-Week Low | $16.87 | $87.56 |
Enterprise Value | $1.26B | $225.54B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
CrowdStrike (CRWD) trades at $214.42, up 3.39% recently, with a bullish technical signal and strong revenue growth, though valuation multiples are high. The company has beaten earnings estimates for three consecutive quarters, with Q2 2026 results pending. Recent news highlights cybersecurity sector strength and AI-driven demand, supported by sold-out events and industry conferences.
Outlook is positive due to robust revenue expansion and platform adoption, but risks include premium valuations and net income volatility. Analyst consensus is strongly bullish with a $191.74 price target, though current price exceeds this, indicating cautious optimism amid growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Crowdstrike Holdings Inc
CrowdStrike Holdings provides cybersecurity products and services aimed at protecting organizations from cyberthreats. It offers cloud-delivered protection across endpoints, cloud workloads, identity and data, and threat intelligence, managed security services, IT operations management, threat hunting, identity protection, and log management. CrowdStrike went public in 2019 and serves customers worldwide.
Read more on CRWD →
